Bone Scanning and Plasma Phosphatases in Carcinoma of the Prostate

O'donoghue, E. P. N.; Constable, A. R.; Sherwood, Thomas; Stevenson, J. J.; Chisholm, G. D.

doi:10.1111/j.1464-410x.1978.tb02797.x

Cited by 65 publications

(18 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study supports the view of other authors that bone scan demonstrates bone métastasés more often than X-ray examination in the initial evaluation of patients with prostatic cancer [8][9][10]. Therefore, if any aggressive diagnostic or therapeutic procedure is planned in patients with prostatic cancer (e.g.…”

Section: -To 8-month Control (18 Patients)supporting

confidence: 78%

Clinical Significance of Routine Follow-Up Examinations in Patients with Metastatic Cancer of the Prostate under Hormone Treatment

Fosså¹,

Heilo²,

Lindegaard³

et al. 1983

Eur Urol

View full text Add to dashboard Cite

Section: -To 8-month Control (18 Patients)supporting

confidence: 78%

Clinical Significance of Routine Follow-Up Examinations in Patients with Metastatic Cancer of the Prostate under Hormone Treatment

Fosså¹,

Heilo²,

Lindegaard³

et al. 1983

Eur Urol

View full text Add to dashboard Cite

“…This remains the most sensitive method of assessing bone metastases, being superior to clinical evaluation, bone radiographs, serum alkaline phosphatase measurement and prostatic acid phosphatase determination [10]. A staging bone scan may be unnecessary if the serum PSA concentration is <10 ng/ml in asymptomatic patients with well or moderately differentiated tumours.…”

Section: Staging Of Capmentioning

confidence: 99%

EAU Guidelines on Prostate Cancer

Abbou²,

et al. 2001

View full text Add to dashboard Cite

Objectives: To develop clinical guidelines for the management of patients with prostate cancer. Methods: Guidelines were compiled by a working panel based on current literature following a literature review using MEDLINE. Already published structured analysis from national and international guidelines was used, and panel consensus was employed when literature evidence was absent or of poor quality. Results: The full text of the guidelines is available through the EAU Central Office and the EAU website (www.uroweb.org). This article summarizes the main conclusions from the guidelines concerning the diagnosis and staging, treatment and follow–up of patients with prostate cancer. The diagnosis of prostate cancer should be based on histopathological or cytological examinations. N– and M–staging may be omitted in selected patients with a low serum prostate–specific antigen due to low risk of metastasis. Active treatment is warranted in most stages of prostate cancer but active monitoring is recommended for elderly patients with early stage tumours and is still optional in some other situations. Follow–up is based on a disease–specific history, serum–prostate–specific antigen supplemented by a digital rectal examination. Routine imaging is not necessary in asymptomatic patients. Conclusions: Prostate cancer is one of the most common malignancies in men. These guidelines have been drawn up to provide support in the management of this large group of patients.

show abstract

“…High-resolution bone imag ing using technetium-labelled phosphate complexes is more sensitive than skeletal radiographs in detecting skeletal métastasés [O'Donoghue et al, 1978;McGregor et al, 1978], The appearance of healing fractures, Paget's disease and inflammatory and degenerative joint disor ders on a bone scan can be mistaken for métastasés, but their site and distribution usually suggest the likely un derlying pathology which may be confirmed by radiolog ical examination. The need to perform repeated scans in patients with bony métastasés has been questioned, it is an expensive test often kept in trial protocols in view of the difficulties in obtaining objective evidence of re sponse by other means.…”

Section: Introductionmentioning

confidence: 99%

Contribution of Bone Scintigraphy, Prostatic Acid Phosphatase and Prostate-Specific Antigen to the Monitoring of Prostatic Cancer

Hetherington¹,

Siddall²,

Cooper³

1988

Eur Urol

View full text Add to dashboard Cite

Changes in the serial measurements of serum prostatic acid phosphatase (PAP), and prostatic specific antigen (PSA) have been compared against changes in serial bone scans in 120 patients with prostatic cancer. Of 54 patients who presented with negative bone scans 10 developed skeletal metastases, the PAP and PSA levels were rising in 5 and 9 of these patients, respectively. Local progression occurred in a further 9 patients in whom PAP was rising in 8 and PSA in all 9. In the 66 patients with previously documented skeletal metastases bone scan evidence of progression was seen in 36. At the time of the first evidence of progression PAP was rising in 20 (55%) and PSA was rising in 26 (72%). In 4 patients neither marker was raised at the time of first evidence of progression. We discuss the value of ‘routine’ serial bone scintigraphy in monitoring patients with prostatic cancer.

show abstract

Bone Scanning and Plasma Phosphatases in Carcinoma of the Prostate

Cited by 65 publications

References 17 publications

Clinical Significance of Routine Follow-Up Examinations in Patients with Metastatic Cancer of the Prostate under Hormone Treatment

Clinical Significance of Routine Follow-Up Examinations in Patients with Metastatic Cancer of the Prostate under Hormone Treatment

EAU Guidelines on Prostate Cancer

Contribution of Bone Scintigraphy, Prostatic Acid Phosphatase and Prostate-Specific Antigen to the Monitoring of Prostatic Cancer

Contact Info

Product

Resources

About